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Abstract
Unto Häkkinen, Tuula Kurki, Antti Vento, Mikko Peltola. Risk Adjustment in Coronary Bypass 
Grafting. How EuroSCORE is related to cost, health-related quality of life, and cost-effectiveness. 
National Institute for Health and Welfare (THL), Discussion Papers 20/2009. 30 pages. Helsinki 
2009.
The aim of this study was to evaluate how EuroSCORE predicts short- and long-term costs and 
outcomes of CABG patients. We analyzed the predictive power of EuroSCORE on various cost 
and outcome measures and evaluated which factors – in addition to the original EuroSCORE 
– affected the measures. We evaluated how patients’ risk scores affected the QALYs gained and 
cost per QALY gained. We also assessed levels of bias in cost and QALY estimates due to the fact 
that HRQoL information is usually available for specific patients who are representative of the 
whole patient population. 
We studied prospectively first-time consecutive coronary bypass patients operated on at 
the Helsinki University Central Hospital between 12/9/2000–21/12/2001. The patient-level risk 
score data was collected preoperatively from almost every patient. HRQoL was measured with 
the 15D. It is a generic, standardized, self-administrated instrument that can be used both as a 
profile and as a single index score measure. The patient-level cost data for the surgical hospital 
admission was based on the cost accounting system of Helsinki University Hospital, which is 
derived through a ”bottom-up approach” and is as such very accurate. In addition, with the use 
of unique personal identification numbers it was possible to link various register data in the 
database, enabling a five-year follow up of patients. 
We evaluated the performance of the risk system using various methods of multivariate 
analysis. Since our analysis is based on a before and after comparison, many important assumptions 
need to be made explicit in order to evaluate the incremental cost effectiveness (CE) ratio (= Δ cost/ 
Δ QALY). Thus we calculated the CE ratio by means of five cost- and two QALY specifications.
According to the results, EuroSCORE was quite strongly associated with costs, various 
mortality indicators and life expectancy but not with HRQoL. In addition to variables included 
in the EuroSCORE, previous-year costs and diabetes were significant additional ”risk factors”. We 
found that changes in HRQoL were heavily dependent on preoperative HRQoL status. CE ratio 
was crucially dependent on QALY measurements and especially on assumptions of the effects 
of treatment on life expectancy. If the operation affected the life expectancy of high risk patients 
more than low risk patients, the cost per QALY difference between the EuroSCORE groups will 
convergence. The cost-per-QALY figures derived from selected samples will overestimate the 
positive results. 
Keywords: Bypass surgery, EuroSCORE, Cost, HRQoL, QALY
5Risk Adjustment in Coronary Bypass Grafting
Discussion Papers 20/2009
THL
Contents
Abstract
1 INTRODUCTION ....................................................................................................................... 7
2 DATA AND METHODS .............................................................................................................8
 2.1 Data ......................................................................................................................................... 8
 2.2 Performance of EuroSCORE .............................................................................................10
 2.3 Cost of QALY gained ..........................................................................................................11
3 RESULTS ......................................................................................................................................14
 3.1 Cost .......................................................................................................................................14
 3.2 Outcomes .............................................................................................................................18
 3.3 Cost per QALY gained ........................................................................................................23
4 CONCLUSIONS .........................................................................................................................27
References .............................................................................................................................................28
7Risk Adjustment in Coronary Bypass Grafting
Discussion Papers 20/2009
THL
1 INTRODUCTION
Meaningful comparisons within health care require risk adjustment - accounting for patient-
associated factors before comparing health care spending, resource utilization across different 
patient groups, treatments, providers, regions, countries or populations. In addition, risk-
stratification models can be used to estimate the need for resources, proper informed consent and 
quality monitoring. During the last decades several models for calculating mortality risk before 
surgery have been developed. For heart surgery, several studies have indicated that EuroSCORE1 
(the European System for Cardiac Operative Risk Evaluation (Nashef et al., 1999; Roques et al., 
1999) performs better than other commonly used preoperative risk scores (Geissler et al., 2000). 
In recent years EuroSCORE has been routinely used in many countries. For example, since 2006 
in Great Britain, cardiac surgical results (adjusted using EuroSCORE) for individual surgical 
units and in some cases for surgeons have been published on the web. In Finland, since 2005 the 
use of EuroSCORE for CABG patients has been included in the National Discharge Register.
EuroSCORE was originally developed using a multinational database of 19 030 patients 
compiled between 1995 and 1999. The 30-day mortality was as an outcome measure. Later, several 
studies analyzed the predictive power of EuroSCORE on cost and length of stay of surgery as 
well as on specific postoperative complications (Hekmat et al., 2005; Tuompoulis et al., 2005). 
However, very seldom have the risk factors been evaluated with respect to health related quality 
of life (HRQoL) (Colak et al., 2008; Jokinen et al., 2008;Loponen et al., 2008).
It has been increasingly recognized that measures of health outcomes should take into account 
both reduced mortality (i.e. increased life expectancy) and quality aspects of life, which enables 
an evaluation of interventions in terms of QALYs (Quality-adjusted life years) gained. In order 
to calculate QALYs we need to know the effects in terms of HRQoLs. Although the feasibility 
of such data collection has been indicated, HRQoL data are not routinely available presently 
(Räsänen 2007), though this may change in the near future, as some countries have started to 
collect such data (Vallance-Owen et al., 2004, Department of Health, 2007). In spite of the many 
practical challenges in this data collection, this kind of information is extremely important for 
productivity (Castelli et al., 2007) and more generally for performance measurement in healthcare 
(Smith et al., 2008).
The aim of this study is to evaluate how EuroSCORE predicts short- and long-term costs and 
outcomes of CABG patients. Firstly, we analyze the predictive power of EuroSCORE on various 
cost and outcome measures and evaluate which factors - in addition to the original EuroSCORE 
– affect the measures. Secondly, we evaluate how patients’ risk-score affects QALYs gained and 
cost per QALY gained. We assess also the bias in cost and QALY estimates due to the fact that 
HRQoL information is usually available only for specific patients who are not representative of 
the whole patient population. 
1	 The	scoring	system	identifies	three	group	of	risk	factors	(patient-related,	cardiac	and	operation	related)	with	their	weights	
(additive%	predicted	mortality)	see	(	http://www.euroscore.org/).
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2 DATA AND METHODS
2.1 Data
First-time consecutive coronary bypass patients operated on at Helsinki University Central 
Hospital (HUCH) between 12/9/2000–21/12/2001 were studied prospectively. The patient-level 
risk score data were collected preoperatively from almost every patient. In addition, other data 
(such as length of hospital stay and ICU length of stay) were collected postoperatively. 
HRQoL was measured with the 15D. It is a generic, standardized, self-administrated 
instrument that can be used both as a profile and single index score measure. It includes 15 
dimensions: mobility, vision, hearing, breathing, sleeping, eating, speech, elimination, usual 
activities, mental function, discomfort and symptoms, depression, distress, vitality and sexual 
activity) (Sintonen, 1994, 1995, 2001). The valuation system of the 15D is based on an application 
of multi-attribute utility theory. A set of utility or preference weights, elicited from the general 
public through a valuation procedure, is used in an additive aggregation formula to generate the 
15D score (single index number) over all the dimensions. The maximum score is 1 (no problems 
on any dimensions) and the minimum score is 0 (being dead). A change ≥ 0.03 in 15D was 
interpreted as being clinically significant.
A questionnaire for gathering demographic information (family background, education) and 
the 15D questionnaire were given to every patient before the operation. The 15D questionnaire was 
also mailed to the patients three months and one year following surgery. The later questionnaire 
included questions concerning the use and cost of health care services after surgery. In addition, 
various register data were linked in the database by means of unique identification numbers. 
This allowed us to follow up patients for five years. Register data included data from the Hospital 
Discharge Register, the Finnish Cause of Death statistics, the registers of the Social Insurance 
Institute and data from the Finnish Hospital Benchmarking Project. Using this data, the costs of 
hospital care (all inpatient care, outpatient visits of specialist hospital care) and costs of prescribed 
medicines in the year previous to and the five years following the operation were calculated. 
Our data also included other risk score systems (Cleveland (Higgins et al., 1992), Northern 
New England (Tu et al., 1995), CABDEAL (Kurki and Kataja, 1996)), but against cost and outcome 
indicators, EuroSCORE performed either better or at least equivalent to the others. 
The patient-level cost data for the surgical hospital admission was based on the cost-
accounting system of HUCH, which is derived through a “bottom-up approach” and is as such very 
accurate. The utilization information for hospital inpatient care (other than surgery admission) 
was converted into costs using Finnish standard costs for different types of health care services 
(Hujanen, 2003). The somatic and other acute hospital inpatient admissions were first grouped 
according to the Finnish version of the NordDRG i.e. Nordic Diagnosis Related Groups. Each 
admission was then converted into costs using average costs per inpatient day, specific to each 
of the DRG groups. The outpatient visits in tertiary hospitals were converted using average cost 
per visit, specific to each specialty and type (emergency /elective) of visit (Peltola et al., 2009). 
All costs were converted to 2001 prices using the municipal health care price index. The costs of 
prescribed medicines were based on information on actual reimbursement at prevailing prices. 
Since the questionnaire included information on costs and utilization up to one year following 
the operation, we were able to estimate those costs that were not included in registries.
We analyzed the cost of i) surgical admission; ii) surgical admission and further hospitalization 
together; iii) first year post-operative; and iv) five years post-operative. Outcomes were analyzed 
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by mortality indices and by survival at five years and changes in for pre- and post-operation 
HRQoL scores. 
Figure 1 describes the total number of CABG patients in the study period and the data used 
in this study. The main analysis was performed using the whole sample (n = 925) which includes 
all patients for whom we had register data well as preoperative risk data. The HRQoL data 
include all 606 patients for whom we had preoperative 15D scores and scores after three months 
or patients who had died within three months. The HRQoL data indicated a clear selection bias 
(Table I). This was verified by estimating a logit regression for the “whole sample” to establish 
the probability of being included in the HRQoL sample. It indicated that in the HRQoL sample, 
costs, 5-year mortality, EuroSCORE status (EuroSCORE 7 or over) and the share of females were 
lower compared to the whole sample.
FIGURE 1. Description of samples
TABLE 1. Patient characteristics
Variable Whole Sample (n = 925) HRQol  sample (n = 606) 
 Mean (%) SD Mean (%) SD 
Age 64,9 9,98 64,1 9,39
Share of females (%) 26,8 44,3 23,7 42,6
Average EuroSCORE 3,77 3,03 3,33 2,59
Cost of surgery admission 14 451 11 096 12 603 7 815
Cost of hospital stay 16 468 16 762 13 874 9 556
One year cost 20 101 16 762 17 172 10 963
Five year cost 30 285 26 442 26 960 20 494
Cost of previous year 3 229 2 315 3 160 2156
30 day mortality 0,035 0,186 0,014 0,12
One year mortality 0,06 0,24 0,026 0,16
Five year mortality 0,148 0,36 0,10 0,29
Diabetes with insulin (%) 0,0832 0,276 0,054 0,23
Total  CABG
patient
population in 
study period
n=1069   Register based 
patient population 
N=925 
(whole sample)
Excluded from 
HRQoL analysis 
n=319
HRQoL patient population 
n=606, of which 10 died 
within three months
(HRQoL sample)
Excluded (refused 98,
not  all register data  16,
not all clinical data 35) 
n=144
Figure 1. Description of samples
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2.2 Performance of EuroSCORE
The performance of the risk system was evaluated using various multivariate analysis methods. 
The analysis was started by including risk scores into the model as bivariate dummy variables and 
as one continuous variable. Since in most cases the continuous specification performed better, 
the modeling was extended using this specification. In the modeling of cost, two extensions for 
the model were made. Firstly, two measures of mortality were included in the model to take into 
account the fact that a patient who died during a hospital stay or after will have been treated more 
intensively during the last days of life, though in the long-term, this would also reduce treatment 
costs. The first measure was a dummy variable for death in the follow-up period, which reflects 
the fact that the costs for those patients who died in surgery are higher than those who survived 
and more generally that the costs of health care are concentrated in proximity to death (Zweifel 
et al., 1999, Häkkinen et al., 2008). This was also found in an earlier Finnish study (Kurki et al., 
2001). The second variable described the survival time and takes into account the fact that costs 
are higher for those who lived longer. This variable is included in the estimation for five-year costs.
 In the second extension, other significant potential risk variables were included. As potential 
risk variables, two clinical factors were considered that are excluded from the EuroSCORE model 
but included in other risk score systems used in heart surgery (Geissler et al., 2000): diabetes with 
insulin and body mass index (BMI). BMI was specified in two alternative ways: 28–30 and > 30. 
However, BMI did not become significant in any models and thus it is not reported in the tables. 
In addition, total health care costs (hospital care and prescribed medicines) for the previous year 
were treated as a potential risk variable, since the variable has in many studies been found to be 
a good predictor of current costs (Ellis, 2007). This may take into account all the costs related to 
co-morbidity more widely than the specific clinical factors included in the EuroSCORE measure.
There is no uniformly agreed upon regression model with which to analyze cost data (Austin 
et al., 2003). Here we modeled the cost variation using a generalized linear model (GLM, gamma 
distribution with log link). GLM was compared with a traditional OLS by calculating the mean 
square error (MSE) for comparing the predictive power of the alternative specifications. The 
comparison was made using EuroSCORE as a continuous variable. In all cases the MSE criterion 
favored GLM over OLS. The better performance of GLM was most clear in one- and five-year costs. 
In the tables, marginal effects are reported since they are more informative than the coefficients 
of a GLM model. The predictive accuracy was measured in terms of R2 and mean absolute error 
(MAD) (Cumming et al. 2002)2 . Althought R2 is not a good measure of the predictive accuracy 
of a GLM model we nevertheless report it since it allows us to compare our result with previous 
studies that have usually applied the OLS model. MAD is a single summary measure of predictive 
accuracy that does not square the prediction errors and so, is not sensitive to large costs. The 
smaller the prediction error, the better the model is performing. However, it is not expressed as a 
standardized scale, so a comparison across studies is not possible. The evaluation of the risk-score 
system for survival was done in a similar way to costs. Survival was analyzed using Cox-regression. 
The predictive power was measured by the area under the receiver operator characteristics (ROC) 
curve after logit regression on 30-day, 90-day, one-year and 5-year mortality. The discriminative 
power of the ROC curve is excellent if the area is >0.80, very good if >0.75 and good if > 0.70. 
In addition the calibration of the logit models was assessed by Hosmer-Lemeshow goodness-
of-fit statistics. For the test, the predicted risk of an individual patient was rank-ordered into 9 
groups3 of equal size, based on their predicted probability. A p value>0.05 indicates an acceptable 
calibration of the model.
The analysis of the changes in 15D was made applying traditional OLS. 
2	 MAD	=(Σ|	ci-^ci|	)/n,	where	ci	is	actual	cost	for	patient	i,	^ c	predicted	cost	for	patient	i	and	n	is	sample	size.	The	“deviation”	
in	MAD	denotes	the	same	quantity	as	“error	“	in	phrase	“mean	squared	error	“	(MSE)	and	the	measures	are	related:	MAD	~	=	
0.8*MSE	(Iezzoni,2003)	
3	 It	is	recommended	that	10	groups	are	the	best	possible	number	of	groups.	However,	in	this	case	only	9	equal	size	risk	
groups	could	be	formed.
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2.3 Cost of QALY gained
The cost-effectiveness analysis (CE) aims to evaluate the incremental ratio:
CE = Δ cost/ Δ QALY
Since our analysis is based on before and after comparisons, many important assumptions should 
be made. In measuring costs we need to define how to measure the change in cost due to the 
operation. Usually only the cost of operation is used as a measure. However, a significant number 
of patients transfer to another department in the hospital or even to another hospital for further 
rehabilitation (at the end of surgery admission), and it can be justified that this should also be 
included in the analysis. In addition, one can argue, that at least a considerable part of other costs 
during the first year following surgery must be included in the costs due to the operation. But 
the inclusion of health care costs for later years is not so straightforward. There is no consensus 
among economic analysts about whether survivors’ medical costs should be included in the 
analysis (Drummond et al., 1997; Gold et al., 1996; Nyman et al., 2004). The question is more 
problematic in a non-randomized study in which there are no ways to separate what part of 
costs and QALY development is due to the operation. Metzler (1997) has made a strong case for 
including future cost in the economic evaluation, particularly if an intervention increases length 
of life. It is customary to subtract any medical savings that are due to effectiveness in treating the 
original disease. Nyman (2004) argues that inclusion of unrelated medical care (i.e. care to treat 
another disease) should be included in the numerator only when the utility from the survival 
medical care is included in the nominator. 
In this study the medical costs for the four years following on from the first year post-
operation (i.e. the costs of the second, third, fourth and fifth year after the operation) were treated 
by two alternative methods. Firstly, they were included in total. This can be seen as a maximum 
cost and is based on the assumption that all patients would have died if the operation had not 
been performed. The second alternative tries to take into account the fact that the operation may 
reduce future treatment costs. This calculation is based on the difference in the annual average 
cost of the last four years post-operatively against the previous year costs before the operation. 
Thus it is assumed that without treatment, the costs would have been the same as they would 
have been for the year before the operation. This calculation is based on the assumption that the 
operation has not affected survival. 
The measurement of QALY gains requires several assumptions, illustrated by Figure 2, adapted 
from Williams (1985) and Castelli et al.( 2007). It plots an individual’s health status—measured 
on the vertical axis, using a scale where 1 indicates full health and 0 indicates death—against 
time. The health stream without the operation is the lowest curve h(ng), with a patient dying at 
time t0. At time t the operation is performed. Treatment initially reduces health but health soon 
improves and health and life is extended to tg as described in the highest curve H(g). There is a 
risk that treatment will kill the patient before he is able to enjoy the improvement associated with 
treatment. Hence the expected health stream, conditional on surviving treatment, is shown by 
the dotted line ah(g). Typically, in before and after comparisons, it is assumed that the difference 
in HRQoL before and after the treatment will prevail for the rest of the life. It is thus assumed 
that the treatment does not affect life expectancy (life expectancy will be t0 in Figure 2). If the 
treatment increases life expectancy, the assumption underestimates the QALY gains (the area 
under the H(g) curve from t0 to tg). The value of this area depends on the difference in the life 
expectancies between patients operated on and those not operated on. If treatment is lifesaving 
(i.e. all patients would have died very soon after if they had not been operated on) the health 
effects will be the whole area under the H(g) curve from t to tg.
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FIGURE 2. Health profile with and without treatment (CABG)
Δ QALY was calculated by two alternative assumptions of life expectancy differences. The 
first (QALY1) is based on a traditional way of assuming that the life expectancy difference is 
minimal. This is based on the difference in the area under ah(g) and h(ng). The difference in 
HRQoL after the operation (q*) and before the operation (q0) is assumed to prevail for the whole 
life. The expected increase in QALYs from operation at time t is:
a q*-q0
where a is the probability of surviving after treatment. The preoperative 15D score is used as 
measure of q0 and the 15D score after three months as a measure of q*. Survival probabilities (a) 
were estimated using a logit model for three months mortality, where the independent variable 
is patients’ EuroSCORE status. The QALY gain is based on changes in HRQoL and patients’ five-
year survival. For those who survived after five years, we estimated the gains for rest of life using 
patients’ age- and gender-specific expected life years from life tables for the whole population 
(Statistics Finland). Thus we assumed that health gains by operation lasted until the end of life. 
We present also the figures for the first five years which are based on observed actual survival. 
Since we do not have HRQoL data for the whole sample we use means for the HRQoL sample 
by risk score groups for those patient with missing data. The expected discounted health gains 
from treatment for patient i were calculated using the formula:
(ak q*i-q0i) ((1-e-rLi)/r)  
where r is the discount rate, ak the expected survival in each EuroSCORE category of patients (k), 
Li the expected life-expectancy of the patient. A 3% discount rate was used for QALY changes 
in future years. 
The second measurement (QALY2) is based on the assumption that without the operation 
all patients would have died. In this case health gains are the area under the ah(g) curve in Figure 
2. It is based on a discounted value for ak * q*i and patients five-year survival. Since health status 
(stock) is deteriorating with age, we include a year factor (-0.002). It is based on the cross-sectional 
effect of age on preoperative 15D status. In addition, we take into account the days that the patient 
has been in hospital receiving inpatient care during the five-year follow-up. It is assumed that in 
those days, a patient’s 15D status has been 0.5.
CE figures were calculated by dividing the cost of surgical admission (COST1), surgical 
admission and further hospitalization together (COST2), first year post-operative (COST3), and 
first-year cost and the difference in the annual average cost of the last four years post-operatively 
h(ng), health without CABG
Difference in
quality of life
X
t tgt0
h(g), health with CABG  
ah (g), health with CABG adjusted with short run survival
Time
Health
1
0
Figure 2. Health prof le wi h an without treatment (CABG)d 
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against the previous year costs before the operation (COST4) by QALY1 and the total discounted 
five-year post-operative cost (COST5) by QALY2. Sensitivity analysis was performed using varying 
discount rates and using upper and lower 95% confidence intervals for the mean differences in 
costs and QALYs. In addition, figures derived from the whole sample were compared to figures 
calculated for the HRQoL sample.  
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3 RESULTS 
3.1 Cost 
The effects of EuroSCORE on time spent in the intensive care unit seem to be stronger than on the 
cost of surgical admission. The risk score is less related to length of stay for the operative admission 
(Figure 3). The risk system explains about 18% of the cost variation in surgery admission and 
the explanatory power increases to 21% when death and diabetes with insulin were included in 
the model (Table 2). The effect of the risk score on costs decreases somewhat when additional 
variables were included in the model. Death during the hospital stay increases the cost by over 
€7000 and patients with diabetes (insulin) were about €4000 more costly than other patients. 
When costs are analyzed for the whole hospitalization (COST2), the effects of risk scores and 
diabetes increases compared to the model of the cost of surgical admission alone. The increase is 
most clear in mortality, which may indicate that severe patients who are going to die are moved 
to another department or hospital.
Figure 3. The relative cost of surgery admission and length of stay in operation admission and in intensive care 
unit according to EuroSCORE level (indices, 100 = average in whole sample)
index 100=average
0
50
100
150
200
250
0 1 2 3 4 5 6 7 over 
7 
time in intensive care unit (days)
cost of surgery admission
time of operation  admission (days)
EuroSCORE
Figure 3. The relative cost of surgery admission and length of stay in 
operation admission and in intensive care unit according to EuroSCORE 
level (Indices, 100 = average in whole sample) .
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THL TABLE 2. GLM estimation on cost of operation admission and whole hospitalisation, marginal effects of coefficients (constant not reported), loglikelyhood and measures of predictive 
accuracy of models
 
 
 
 
Cost of surgical admission Cost of surgical admission and further hospitalization together
Dummy 
specification of risk 
score
Continuous specification of risk score
Dummy 
specification of risk 
score
Continuous specification of risk score
Restricted 
specification
Restricted 
specification
Restricted 
specification +death
Extended 
specification
Restricted 
specification
Restricted 
specification
Restricted 
specification +death
Extended 
specification
marginal 
effects
z-value marginal 
effects
z-value marginal 
effects
z-value marginal 
effects
z-value marginal 
effects
z-value marginal 
effects
z-value marginal 
effects
z-value marginal 
effects
z-value
EuroSCORE   1 122 11,2 1 048 10,4 1 028 10   1 549 12,02 1 393 11,15 1 356 11,19
EuroSCORE , O reference value
1 3 555 2,9       4 510    2,6        
2 1 954 1,8       2 661    1,7        
3 2 625 2,4       4 435    2,8        
4 4 187 3,3       6 521    3,6        
5 4 720 3,6       7 491    4,0        
6 8 481 4,8       12 375    5,3        
7 12 228 5,5       18 438    6,6        
over 7 17 825 8,3       27 663   10,5        
Death during the follow 
up (1 if death)
    7 891 2,35 7 313 2,3     19 019 4,4 17 701 4,3
Diabetes insulin 
(1 if user)
      4 239 3,5       6 015 3,92
Previous years cost/€1000
log likelyhood -13 929  -9 752  -9 747   -9 748   -9 857  -9 858  14 047  -14 047   
R2 0,14  0,18  0,20  0,21  0,16  0,17  0,20  0,23  
MAD 5 762  5 655  5 558  5 531  7 373  7 265  7 101  7 040  
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The cost of surgery admission accounts for 70–80% of the total one-year health care cost of 
those patients who were alive after one year and completed the questionnaire (Figure 4). The share 
was highest among low-score patients and lowest among those whose risk score was 7 or higher. 
Patients with a risk score higher than 4 had much greater costs related to the additional use of 
hospital care either by additional hospital days immediately after operating admission, or later 
in the year in the form of new hospitalizations or use of hospital outpatient services. Prescribed 
medicines as well as other use of outpatient services were divided rather evenly according to risk 
score groups. The health care costs (outpatient visits in primary care as well as OTC medicines) for 
which no information was available in the registers accounted for only 2–4% of total one-year costs.
Risk score was associated with one-year total cost of health care to about the same degree 
(R2 = 0.17) as in shorter-term cost estimates (Table 3). The inclusion of other significant variables 
in the model increased further the explanatory power by 3 percentage points. Severe diabetes 
increased first-year costs by €7600. Contrary to shorter-time cost estimates, the previous-year 
costs now also became significant: an increase of €1000 in the previous-year costs increased the 
one-year post-operative cost by €700. 
FIGURE 4. The composition of the first year cost according to EuroSCORE status of patients. Based on those alive 
patients who filled the follow-up questionnaire (n = 533)
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Figure 4. The composition of the first year cost according to EuroSCORE 
status of patients. Based n tho e alive patients wh  filled the follow-up 
questionnaire (n=533)
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THL TABLE 3. GLM estimation on first and five years post-operative costs ( marginal effects of coefficients (constant not reported), loglikelyhood and measures of predictive accuracy of models) 
 
 
 
 
First year cost Five year cost
Dummy 
specification of risk 
score
Continuous specification of risk score
Dummy 
specification of risk 
score
Continuous specification of risk score
Restricted 
specification
Restricted 
specification
Restricted 
specification +death
Extended 
specification
Restricted 
specification
Restricted 
specification
Restricted 
specification +death
Extended 
specification
marginal 
effects z-value
marginal 
effects z-value
marginal 
effects z-value
marginal 
effects z-value
marginal 
effects z-value
marginal 
effects z-value
marginal 
effects z-value
marginal 
effects z-value
EuroSCORE   1 776 12 1 594 10,74 1 540 11,4   2 543 9,46 2 137 8,07 2 118 9,14
EuroSCORE , O reference value
1 5 963 3 ,02       7 519 2,30       
2 4 773 2,54       10 183 3,12       
3 5 721 3,12       9 895 3,18       
4 9 166 4,39       17 483 4,81       
5 10 590 4,9       25 837 6,49       
6 14 497 5,48       23 423 5,20       
7 21 653 6,9       36 604 6,73       
over 7 31 512 10,8       38 878 8,47       
Death during the 
follow up (1 if death)
    9 322 4,11 7 290 3,59     25 780 4,83 18 120 4,11
Days lived in follow-up             8,5 2,63 7,7 2,72
Diabetes insulin 
(1 if user)
      7 646 4,49       13 068 4,6
Previous years 
cost/€1000
      696 4,01       1 909 5,94
log likelyhood -14 339  -14 339  -9 731   -9 691   -10 434    -10 438  -10 427  -10 405    
R2 0,15  0,17  0,17  0,21  0,10  0,10  0,13  0,26  
MAD 8 945  8 798  8 648  8 460  14 913  14 929  14 306  13 379  
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About 80% of the five-year cost was devoted to hospital care (Figure 5). The share of hospital 
care was highest (87%) among patients with a risk score >7 and lowest (25%) among patients 
with a risk score of 0. The cost of surgery admission alone accounted for about 48% of the five-
year costs. However, after the first year, some 50% of costs derive from the use of prescribed 
medicines. The five-year costs are related to mortality and survival time in two ways as expected. 
The mortality increased costs by €26 000. On the other hand, an increase of life expectancy by 
1 day increased costs by €8 i.e. increased survival by one year will increase costs by €3100. The 
EuroSCORE status together with mortality and survival explained 13% of the variation in five-
year costs. The explanatory power increased to 26% when diabetes status (effect €13 000) and 
previous year’s health care were included in the model (Table III). Their inclusion decreases the 
effects of mortality and survival time.
FIGURE 5. Five years cost of hospital care (including outpatient visits in specialist care) and prescribed medicines 
according to EuroSCORE status of patients. Based on alive patients after five years (n = 788)
3.2 Outcomes
The average change between the three-month 15D and postoperative 15D score was 0.041 
(+/- 0.008) among those who survived the follow-up. Most of the improvement occurred during 
the first three months and by the one-year follow-up the 15D score somewhat decreased. After 
three months, 35% (32% after one year) of patients had a clinically significant (> 0.003) increase 
in 15D. Clinical improvement was evident in 46.0% (40.3% after one year) of patients with a risk 
score of 0, 41.3% (39.4% ) with a risk score of 1, 38.0% (38.0% ) with a risk score of 2, 39.1% 
(37. 6%) with a risk score of 3, 37.0% (36.1%) with a risk score of 4, 21.2% (19.3%) with a risk 
score of 5, 33.8% (29.4% ) with a risk score of 6, 32.1% (23.2%) with a risk score of 7 and 11.7% 
(16.0%) with a risk score >7.
The most important positive changes in 15D occurred in moving, breathing and vitality 
(Figure 6). Risk score was not very clearly associated with changes in HRQoL. The change 
was highest among those with a risk score of 0 and also clearly positive among patients with a 
score > 4 (Figure 7). The EuroSCORE’s explanatory power was very low (Table 4) and increased 
considerably when the initial 15D score was included in the model. The effect of the initial 15D 
score was negative, indicating that the operation benefited most of those patients whose initial 
health status was worse. The change in HRQoL was smaller among patients who had a higher 
health care cost than in the previous year. 
€/patient
0
5 000
10 000
15 000
20 000
25 000
30 000
35 000
40 000
45 000
50 000
EuroSCORE
0 1 2 3 4 5 6 7 over 7
Hospital care
Prescribed medicines
Figure 5. Five years cost of hospital care (including outpatient visits in 
specialist care) and prescribed medicines  according to EuroSCORE status of 
patients. Based on alive patients after five years (n=788) 
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FIGURE 6. The 15 dimensions and mean 15D score of health before, 3 and 12 months after by CABG (HRQoL 
sample deaths included)
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Figure 6. Th  15 dimensio s and mean 15D sc re of health before, 3 and 12
months aft r by CABG (HRQol sample deaths included)
FIGURE 7. The average change (and its confidence intervals) of 15D score between three months after and before 
CABG operation according to EuroSCORE status of patients, HRQoL sample death excluded
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Figure 7. The average change (and its confidence intervals) of 15D score between 
three months after and before CABG  operation according  to EuroSCORE status 
of patients,  HRQol sample death excluded 
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TABLE 4. OLS estimation on change in 15D score (after 90 days year and before operation) and logit model for 90 day mortality 
 
 
 
 
OLS for 15D change (HRQoL sample), deaths excluded logit for 90 day mortality (whole sample)
Dummy specification 
of riskscore
Continous spefification of riskscore
Dummy specification 
of riskscore
Continous spefification of riskscore
Restricted 
specification
Restricted 
specification
Extended 
specification
Restricted 
specification
Restricted 
specification
Extended specification
coeff. t-value coeff. t-value coeff. t-value marginal 
effects
z-value marginal 
effects
z-value marginal 
effects
z-value
Constant 0,073 7,15 0,058 8,27 0,428 14,03 0,062 5,93     
EUROscore   -0,005 9,18 -0,007 -4,91   0,008 7,87 0,008 -4,82
EUROscore , O reference value 
1 -0,032 -2,16          
2 -0,033 -2,26     0,015 0,46     
3 -0,025 -1,86     0,011 0,36     
4 -0,034 -2,24     0,076 1,63     
5 -0,058 -3,53     0,105 1,98     
6 -0,046 -2,56     0,297 3,21     
7 -0,030 -1,47     0,205 2,55     
over 7 -0,069 -3,6     0,410 3,94     
Preoperative 15 D score     -0,425 -12,53       
Previous years cost/€1000     -0,004 -2,49     0,002 2,63
R2 /pseudo R2 0,03  0,02  0,22  0,19  0,20  0,21  
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The EuroSCORE model had very good discriminatory ability against most of the mortality 
indicators (Table 5). Only for five-year mortality was the area under the ROC curve under 80. In 
all except one-year mortality the Hosmer-Lemeshow test also showed good calibration. In most 
cases the extended model performed somewhat better than the restricted model. Previous-year 
costs and diabetes with insulin (five-year mortality) seemed, in addition to the risk score, to be 
an important factor for explaining mortality. Both variables were also significant predictors for 
5-year survival (Table 5) in the whole sample but not in the HRQoL sample.
In the whole sample, the patients with a EuroSCORE ≥ 7 had the highest hazard rate and 
they were clearly distinct from other patients (Table 6). The five-year mortality in this group was 
40%. Patients with a risk score of 6 or 7 had rather a high hazard rate, which was also higher than 
patients with lower risk scores. Only one person who had a EuroSCORE of 0 died within five 
years. A comparison of hazard rates between the whole sample and the HRQoL sample indicates 
again the selection of less severe patients to the HRQoL group. 
TABLE 5. Validity of EuroSCORE on different measures of mortality
Mortality indicator
 
Model
 
Pseudo-R2
 
Hosmer-Lemeshow after 
logit model
Area under 
ROC
chi2 p  
30 day mortality Restricted model 0,1638 8,29 0,3081 0,8178
90 day mortality Restricted model 0,1976 8,21 0,3144 0,8384
 
Extended (previous 
year cost)
0,2124 9,29 0,2328 0,8483
one year mortality Restricted model 0,1764 13,9 0,053 0,83
 
Extended (previous 
year cost)
0,1888 14,39 0,0446 0,8388
five year mortality Restricted model 0,1275 12,74 0,0787 0,7698
 
Extended 
(preivious year 
expenditure,diabets 
with insulin)
0,1515 9,58 0,2136 0,7844
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TABLE 6. Estimation results of a cox regression model (five years follow-up)
EuroSCORE Whole sample HRQoL sample
Dummy specification of 
risk score Continous spefication of risk score
Dummy specification of 
risk score
Continous spefification of 
risk score
Restricted specification Restricted specification Extended specification Restricted specification Restricted specification
hazard ratio z-value hazard ratio z-value hazard ratio z-value hazard ratio z-value hazard ratio z-value
EuroSCORE   1,27 11,03 1,28 10,82   1,206 4,72
EuroSCORE, O and 1 (reference values) 
2 3,9 2,22     5,3 2,43   
3 6,4 3,30     4,5 2,23   
4 9,9 4,13     8,6 3,33   
5 10,3 4,20     6,4 2,62   
6 20,0 5,47     12,5 3,79   
7 22,3 5,62     14,5 3,78   
over 7 31,6 6,57     11,6 3,55   
Diabetes insulin (1 if user)     1,77 2,41     
Previous years cost/€1000     1,08 3,87     
log likelyhood -866  -874  -865  -351  -357   
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3.3 Cost per QALY gained
All incremental cost measures increased with risk scores (Table 7). In the lowest risk score groups, 
annual costs even decreased when they were compared with the cost before the operation. The 
estimated QALY gains were positive in the five lowest EuroSCORE groups, when calculation was 
based on an assumption of no effects on life expectancy (QALY1). However, if an extreme effect 
of life expectancy is assumed (i.e. without an operation all patients would have died) the QALY 
gains were rather high even in the highest risk score groups (Table 8). The cost per QALY gained 
were dependent on both the cost and the QALY measures. The average incremental cost per 
QALY varied between €60 000–€85 000 when only a change in the quality components of life is 
assumed and was reduced by about one tenth when an extreme effect of life expectancy is assumed. 
The CE increases greatly with risk score level. In the extreme assumption of life expectancy, the 
cost per QALY gained has been rather low even among patients with high risk scores (Table 9). 
Sensitivity analyses indicated that the measurement of QALY was the most critical (Table 10). In 
addition, the CE figures derived from the HRQoL sample were 40% lower compared to respective 
figures derived from the whole sample (Figure 8). The difference was due to two reasons: HRQoL 
sample underestimated the cost and overestimated the QALY gains. Only in COST5/QALY2 was 
the difference between the two samples small. 
TABLE 7. Estimates of incremental cost of CABG patients according to EuroSCORE status
Cost of 
surgery 
admission 
(COST1)
Cost of 
surgical 
admission 
and further 
hospitalization 
together 
(COST2)
Cost of first 
year (COST3)
Annual cost 
differnce 
(aveage) of 
following 
four years 
against one 
year before 
operation 
( 3% discount 
rate)
First year cost 
(COST3) and 
cost differnce 
in following 
four years 
Cost of 
following four 
years (3 % 
discount rate)
Total five 
year cost (3% 
discount rate) 
COST5
COST 1 COST2 COST3 ACC COST4 
(=COST3+ACC)
C4Y COST5 
(=COST3+C4Y)
EuroSCORE
0 10 342 10 642 12 914 -4 694 8 220 5 379 18 293
1 13 047 13 812 17 054 -4 166 12 888 6 177 23 230
2 11 814 12 495 16 218 -2 623 13 595 8 594 24 812
3 12 338 13 787 16 919 -625 16 294 7 811 24 730
4 13 541 15 278 19 370 415 19 785 10 352 29 723
5 13 955 15 987 20 404 7 238 27 642 14 914 35 318
6 16 850 19 460 23 078 310 23 388 10 477 33 555
7 19 756 23 839 28 164 5 426 33 590 14 060 42 224
over 7 24 762 31 711 36 437 4 245 40 682 9 067 45 504
Averege 14 451 16 468 20 101 86 20 188 9 192 29 293
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TABLE 8. Post and preoperative HRQoL, short run survival, life extepectancy and QALYs according to EuroSCORE status
EuroSCORE
 
 
HRQoL (15D) Short run 
(3 months) 
survival
 
Averege life 
expectancy 
of the 
survived
 
QALY1 QALY2
preopertive 
(N = 596)
 
3 months 
after 
opeation 
(n = 596)
 
differnce 
between 
3 months 
follow-
up and 
preoprative 
(N = 596)
 
1 year after 
operation 
(n = 570)
 HRQoL sample whole sample
HRQoL 
sample
 
Whole 
sample
 
five years whole life five years whole life
0 0,828 0,901 0,073 0,897 0,994 26,483 0,310 1,211 0,265 1,039 4,084 4,070
1 0,831 0,872 0,041 0,871 0,991 24,846 0,151 0,544 0,150 0,564 3,924 3,959
2 0,844 0,884 0,040 0,889 0,987 20,856 0,127 0,394 0,128 0,413 3,950 3,944
3 0,838 0,886 0,047 0,886 0,981 17,436 0,148 0,494 0,138 0,444 3,895 3,827
4 0,852 0,891 0,039 0,873 0,974 14,920 0,081 0,246 0,092 0,272 3,727 3,569
5 0,831 0,846 0,015 0,842 0,963 14,397 -0,068 -0,086 -0,033 -0,030 3,546 3,494
6 0,820 0,846 0,027 0,846 0,948 13,106 -0,039 0,009 -0,062 -0,064 3,453 3,423
7 0,745 0,787 0,042 0,779 0,928 12,064 -0,012 0,002 -0,058 -0,109 3,039 2,932
over 7 0,811 0,815 0,004 0,812 0,780 11,126 -0,662 -1,555 -0,621 -1,418 2,776 2,521
Average 0,830 0,871 0,041 0,868 0,956 18,287 0,073 0,331 0,042 0,239 3,745 3,634
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TABLE 9. Cost per QALY gained according to EuroSCORE status
EuroSCORE
Cost of 
Surgery 
admission 
(COST 1)/
QALY1
Cost of surgical 
admission 
and further 
hospitalization 
together 
(COST2)/
QALY1
Cost of first 
year (COST 3)/ 
QALY1
 Cost of first 
year and cost 
differnce in 
four following 
years (COST4)/
QALY1
Cost of five 
years (COST 5)/
QALY
0 9 954 10 243 12 430 7 912 4 494
1 23 144 24 502 30 252 22 862 5 868
2 28 601 30 249 39 263 32 913 6 290
3 27 780 31 042 38 093 36 687 6 462
4 49 696 56 073 71 092 72 615 8 329
5 a a a a 10 109
6 a a a a 9 804
7 a a a a 14 403
over 7 a a a a 18 052
totally 60 496 68 938 84 149 84 511 8 061
TABLE 10. Sensitivity of cost of first year (COST3) per QALY1 estimates
EuroSCORE
Discount rate for QALY1 Cost estimate 
(QALY1 fixed)
QALY1 estimate 
(COST 3 fixed )
not 
discounted
5% discount 
rate
upper 95%l lower 95% upper 95%l lower 95%
0 8 537 15 488 13 373 11 488 9 759 17 114
1 20 797 37 521 35 075 25 428 20 288 59 445
2 28 812 47 170 43 254 35 272 26 293 77 490
3 27 718 45 868 42 484 33 703 24 336 87 625
4 53 585 83 971 82 541 59 643 42 992 205 225
5 á a a a 139 518 a
6 a a a a 103 794 a
7 a a a a 264 899 a
over 7 a a a a   
totally 55 011 108 453 88 677 79 621 60 406 138 642
a = Can not be established
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FIGURE 8. A comparison of C/E estimates calculated from whole and HRQoL sample
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Figure 8. A comparison of C/E estimates calculated from whole and HRQoL sample
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4 CONCLUSIONS 
Of the earlier studies on EuroSCORE and the hospital cost of cardiac surgery, our result (R2 = 
0.19) were similar to Pintor et al. (2003) ( R2 = 0.22 ), Sokolovic et al. (2002) (R2 = 0.19) and 
Nielson et al. (2004) (0.22), though we found a stronger relationship than Hekmat et al. (2005) 
(R2 = 0.05). In addition, in our study EuroSCORE predicts to some extent also the one-year and 
even five-year costs. The prediction of cost can be somewhat improved by including two additional 
postoperative variables (previous year cost and diabetes with insulin).
The EuroSCORE model, initially designed to predict 30-day mortality, also satisfactory 
predicted one-year mortality and even five-year survival. Again the two variables improved 
the predictions. However, the risk stratification model does not greatly predict the changes in 
HRQoL. As in a previous Finnish study (Loponen et al., 2008) a significant difference in changes 
in HRQoL between low-risk and high-risk patients was found. A recent Croatian study (Colak et 
al., 2008) using a small sample (111) indicated the opposite: patients with a high operative risk 
(EuroSCORE ≥ 6) were likely to experience significant improvement in a greater number of health 
domains (using SF 36 scores) compared to patients with low and medium risks (EuroSCORE 
< 6). However, the results are not comparable because they used a different HRQoL measure, 
which were used only as a profile measure. The Finnish experience indicates that EuroSCORE 
does separate patients into 2–3 groups according to changes in HRQoL but does not perform 
well as a predictive model for the changes. For example, initial HRQol status predicts HRQoL 
changes much better than EuroSCORE.
According to our calculation the average cost per QALY was among patients with a risk score 
of less than 2, at usually less than €30 000–40 000, which has sometimes been used as a maximum 
that society is willing to pay for an extra QALY. However the CE ratio is crucially dependent on 
measuring QALYs and specially the assumptions on the effects of treatment on life expectancy. 
If the operation affects the life expectancy of high risk patients more than low risk patients, the 
CE difference between risk score groups will convergence.
Nowadays it is widely accepted that measures of outcome and even the outputs of health 
should be based on QALYs. Usually the effects of treatment have been estimated using the 
difference in HRQoL before and after treatment. It is suggested that this kind of data enables a 
comparison between providers, regions, countries or years. However, our study indicates clear 
challenges in the routine collection of outcome data. Although we managed to get HRQoL data 
for about 65% of patients, the sample was clearly selective, affecting crucially the CE ratios. For 
example, an average CE ratio (COST1/QALY1) will decrease from € 60 000 to € 38 000 (40%) 
when it is estimated from the HRQoL sample rather than the whole sample. This indicates that 
many previous studies based on patient-reported changes in HRQol have seriously overestimated 
the real health benefits of treatments and thus also the COST per QALY gained. 
Our study indicates that a routine collection of risk scores together with register-based 
measurement of costs and outcomes give much more information for operational planning. 
Specific attention should be paid to high risk groups because the HRQoL changes are rather 
modest among patients with a EuroSCORE higher than seven, or who have extended ICU stays, 
high mortality and costs.
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